PUXEDDU, ERMANNO
 Distribuzione geografica
Continente #
NA - Nord America 13.097
EU - Europa 1.261
AS - Asia 758
Continente sconosciuto - Info sul continente non disponibili 8
SA - Sud America 8
OC - Oceania 7
AF - Africa 4
Totale 15.143
Nazione #
US - Stati Uniti d'America 13.070
SG - Singapore 293
KR - Corea 237
IT - Italia 226
DE - Germania 183
FR - Francia 178
IE - Irlanda 166
CN - Cina 152
UA - Ucraina 140
PL - Polonia 123
GB - Regno Unito 82
FI - Finlandia 42
SE - Svezia 41
RU - Federazione Russa 33
CA - Canada 19
IN - India 19
BE - Belgio 14
JP - Giappone 11
MX - Messico 8
AU - Australia 7
MY - Malesia 7
NL - Olanda 7
HK - Hong Kong 6
KG - Kirghizistan 6
RO - Romania 6
TR - Turchia 6
VN - Vietnam 6
BR - Brasile 5
ES - Italia 5
EU - Europa 5
HU - Ungheria 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AE - Emirati Arabi Uniti 2
BD - Bangladesh 2
CH - Svizzera 2
CL - Cile 2
GR - Grecia 2
IQ - Iraq 2
LY - Libia 2
RS - Serbia 2
SA - Arabia Saudita 2
TW - Taiwan 2
AM - Armenia 1
AT - Austria 1
AZ - Azerbaigian 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
EC - Ecuador 1
EE - Estonia 1
EG - Egitto 1
ID - Indonesia 1
IR - Iran 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MA - Marocco 1
Totale 15.143
Città #
Woodbridge 3.477
Wilmington 3.421
Houston 3.372
Fairfield 497
Ann Arbor 318
Chandler 308
Singapore 253
Seattle 212
Ashburn 197
Cambridge 167
Dublin 134
Kraków 119
Jacksonville 103
Medford 102
Dearborn 69
Beijing 64
New York 64
Santa Clara 62
Rome 55
Lawrence 49
Menlo Park 32
Redwood City 23
San Diego 20
Palo Alto 18
Brussels 14
Helsinki 14
Moscow 14
Milan 12
Verona 12
Zhengzhou 12
Guangzhou 11
London 11
Seoul 10
Los Angeles 9
Boardman 8
Nanjing 8
Norwalk 8
Liverpool 7
Wuhan 7
Mountain View 6
Phoenix 6
Shanghai 6
Hefei 5
Istanbul 5
Kunming 5
Munich 5
Mülheim 5
San Jose 5
Shirwal 5
Surrey 5
São Paulo 5
Delhi 4
Dong Ket 4
East Haven 4
Osaka 4
Pescara 4
Vaughan 4
Ancona 3
Chaah 3
Chula Vista 3
Ciudad Obregón 3
Columbia 3
Detroit 3
Genoa 3
Hanover 3
Highlands Ranch 3
Hyderabad 3
Iasi 3
Jinan 3
Kilburn 3
Monza 3
Raleigh 3
Redmond 3
Saint Petersburg 3
San Francisco 3
Stockholm 3
University Park 3
Wanchai 3
Xian 3
Agropoli 2
Amherst 2
Arezzo 2
Aurora 2
Baghdad 2
Benito Juarez 2
Bicester 2
Birmingham 2
Bologna 2
Budapest 2
Canberra 2
Carugate 2
Chaoyang 2
Chengdu 2
Chester 2
Chongqing 2
Collegeville 2
Colorado Springs 2
Concorezzo 2
Cupertino 2
Duncan 2
Totale 13.488
Nome #
Idiopathic Pulmonary Fibrosis (IPF) incidence and prevalence in Italy 610
Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells 461
Interaction between corticosteroids and muscarinic antagonists in human airways 452
An unusual outbreak of nontuberculous mycobacteria in hospital respiratory wards: Association with nontuberculous mycobacterial colonization of hospital water supply network 436
A 6MWT index to predict O2 flow correcting exercise induced SpO2 desaturation in ILD 435
Onset of action of budesonide/formoterol Spiromax® compared with budesonide/formoterol Turbuhaler® in patients with COPD 435
Effect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterol. 428
Optimizing drug delivery in COPD: The role of inhaler devices 422
LABA/LAMA combination in copd: A meta-analysis on the duration of treatment 416
Airflow obstruction: Is it asthma or is it COPD? 414
M. avium binding to HLA-DR expressed alleles in silico: A model of phenotypic susceptibility to sarcoidosis 412
Metodo per la diagnosi in vitro di fibrosi polmonare/polmonite interstiziale idiopatica e uso di chelanti del ferro per il trattamento della fibrosi polmonare/polmonite interstiziale idiopatica 409
Is allergic sensitization to siberian hamster preventable in high-risk individuals who are already sensitized or exposed to furry animals? 406
null 405
Therapeutic use of heparin and derivatives beyond anticoagulation in patients with bronchial asthma or COPD 401
Reactivity to mycobacterial antigens by patients with Lofgren's syndrome as a model of phenotypic susceptibility to disease and disease progression. 396
The prevalence of asthma and COPD in Italy: a practice-based study 394
The Time Course of Pulmonary Function Tests in COPD Patients with Different Levels of Blood Eosinophils 389
An overview of the current management of chronic obstructive pulmonary disease: can we go beyond the GOLD recommendations? 382
Iron laden macrophages in idiopathic pulmonary fibrosis: The telltale of occult alveolar hemorrhage? 379
Impact of pulmonary vascular volume on mortality in IPF: Is it time to reconsider the role of vasculature in disease pathogenesis and progression? 375
Acute COPD exacerbation: 3 T MRI evaluation of pulmonary regional perfusion--preliminary experience. 368
Effect of adding roflumilast or ciclesonide to glycopyrronium on lung volumes and exercise tolerance in patients with severe COPD: A pilot study 364
Searching for the synergistic effect between aclidinium and formoterol: From bench to bedside 360
null 359
Emerging biological therapies for treating chronic obstructive pulmonary disease: A pairwise and network meta-analysis 347
Gender-related Responsiveness to the Pharmacological Treatment of COPD: A First Step Towards the Personalized Medicine 344
Human embryonic stem cells recover in vivo acute lung inflammation bleomycin-induced 341
Structured multidisciplinary discussion of HRCT scans for IPF/UIP diagnosis may result in indefinite outcomes 340
Adherence to COPD treatment: Myth and reality 336
Relationship between oxytocin/vasopressin and latex in obstetric surgery: How to recognize (and prevent) allergic reactions and differentiate them from side effects? 335
Dual bronchodilation and exacerbations of COPD 322
DIAGNOSTIC PERFORMANCE AND SAFETY OF BRONCHOALVEOLAR LAVAGE IN THROMBOCYTOPENIC HAEMATOLOGICAL PATIENTS FOR ASPERGILLOSIS DIAGNOSIS: A MONOCENTRIC, RETROSPECTIVE EXPERIENCE 319
Method for in vitro diagnosis of idiopathic pulmonary fibrosis 310
Human embryonic stem cells recover in vivo acute lung inflammation bleomycin-induced 307
Olodaterol + tiotropium bromide for the treatment of COPD 207
The prognostic role of Gender-Age-Physiology system in idiopathic pulmonary fibrosis patients treated with pirfenidone 207
Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine 197
Depressive and anxiety symptoms in patients with SARS-CoV2 infection 164
Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: A bidimensional comparative analysis across fixed-dose combinations 145
A potential role of triple therapy for asthma patients 134
null 119
Biomarkers for possible early detection and progression of idiopathic pulmonary fibrosis 76
CD71- Alveolar Macrophages in Idiopathic Pulmonary Fibrosis: A Look beyond the Borders of the Disease 73
Does bronchoscopy help the diagnosis in COVID-19 infection? 62
Dyspnea perception and neurological symptoms in non-severe COVID-19 patients 52
Efficacy and safety of triple combination therapy for treating chronic obstructive pulmonary disease: an expert review 48
HFE gene variants and iron-induced oxygen radical generation in idiopathic pulmonary fibrosis 44
Experimental Glucocorticoid Receptor Agonists for the Treatment of Asthma: A Systematic Review 36
A safety comparison of LABA+LAMA vs LABA+ICS combination therapy for COPD 32
Are there pulmonary sequelae in patients recovering from COVID-19? 28
Evolving Concepts in Chronic Obstructive Pulmonary Disease Blood-Based Biomarkers 26
Acute effect of oxygen therapy on exercise tolerance and dyspnea perception in ILD patients 22
Impact of long-acting muscarinic antagonists on small airways in asthma and COPD: A systematic review 20
Synergy across the drugs approved for the treatment of asthma 16
Totale 15.317
Categoria #
all - tutte 30.814
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.814


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20203.221 0 0 0 363 406 457 356 374 413 305 286 261
2020/20212.574 253 304 261 275 293 264 410 248 74 64 89 39
2021/2022599 31 56 18 30 25 51 66 28 35 76 51 132
2022/2023734 79 80 22 84 87 153 63 42 63 15 26 20
2023/2024346 55 18 50 10 16 69 18 15 8 17 18 52
2024/2025521 44 317 142 18 0 0 0 0 0 0 0 0
Totale 15.317